SCHEMBL20103534

SCHEMBL20103534

Cc1ccc(F)c(C2CCC(C)CC2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 5/20 0.41
SLC6A4 P31645 5/20 0.41
SLC6A3 Q01959 4/20 0.41
HTR1A P08908 2/20 0.41
CHRNB2 P17787 1/20 0.37
CHRNA4 P43681 1/20 0.37
ESR2 Q92731 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
TAS1R3 Q7RTX0 2/20 0.36
TAS1R1 Q7RTX1 2/20 0.36
TAS1R2 Q8TE23 2/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.34
HTR2C P28335 2/20 0.33
GLA P06280 1/20 0.33
KMT2A Q03164 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MEN1 O00255 1/20 0.33
DRD4 P21917 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12024476 0.92 SLC6A2 (0.45) SLC6A2SLC6A4SLC6A3HTR1ACHRNB2
SCHEMBL18503369 0.85 SLC6A2 (0.39) SLC6A2SLC6A4SLC6A3HTR1ACHRNB2
SCHEMBL13103961 0.85 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3HTR1ACHRNB2
SCHEMBL10206355 0.85 PTGDR2 (0.45) SLC6A2SLC6A4SLC6A3HTR1ACHRNB2
SCHEMBL765036 0.83 PTGDR2 (0.48) SLC6A2SLC6A4SLC6A3HTR1ACHRNB2
SCHEMBL18503370 0.81 SLC6A2 (0.37) SLC6A2SLC6A4SLC6A3HTR1ACHRNB2
SCHEMBL13993850 0.79 APP (0.44) SLC6A2SLC6A4SLC6A3HTR1ADRD4
SCHEMBL11096658 0.78 TAS1R3 (0.45) CHRNB2CHRNA4ESR2CA1CA2
SCHEMBL13401946 0.77 OPRL1 (0.46)
SCHEMBL16962148 0.76 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3HTR1ACHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018081047-A1 CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 WO disclosed